Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Free Report) CEO Emil D. Kakkis sold 20,000 shares of the business’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
Ultragenyx Pharmaceutical Price Performance
RARE stock traded down $0.22 during mid-day trading on Thursday, reaching $55.90. The company had a trading volume of 90,648 shares, compared to its average volume of 799,793. The company has a market capitalization of $5.15 billion, a PE ratio of -6.99 and a beta of 0.56. The firm has a 50 day moving average of $48.27 and a 200 day moving average of $45.90. Ultragenyx Pharmaceutical Inc. has a 12 month low of $31.52 and a 12 month high of $58.73.
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) last issued its earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.52) EPS for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.12. The business had revenue of $147.03 million for the quarter, compared to the consensus estimate of $123.20 million. Ultragenyx Pharmaceutical had a negative net margin of 121.57% and a negative return on equity of 266.02%. The company’s revenue for the quarter was up 35.7% compared to the same quarter last year. During the same period in the prior year, the firm earned ($2.25) EPS. Analysts anticipate that Ultragenyx Pharmaceutical Inc. will post -6.24 EPS for the current year.
Hedge Funds Weigh In On Ultragenyx Pharmaceutical
Wall Street Analyst Weigh In
RARE has been the topic of several research analyst reports. Barclays decreased their price target on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. The Goldman Sachs Group boosted their price target on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a research note on Friday, August 2nd. Canaccord Genuity Group restated a “buy” rating and set a $111.00 target price on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, July 23rd. Stifel Nicolaus upped their target price on shares of Ultragenyx Pharmaceutical from $124.00 to $127.00 and gave the company a “buy” rating in a research report on Friday, May 31st. Finally, Bank of America decreased their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $76.00 and set a “buy” rating on the stock in a research report on Friday, May 31st. Two equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to data from MarketBeat.com, Ultragenyx Pharmaceutical currently has an average rating of “Moderate Buy” and a consensus target price of $87.43.
Check Out Our Latest Stock Analysis on Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
See Also
- Five stocks we like better than Ultragenyx Pharmaceutical
- Stock Average Calculator
- Recession or Not, These 3 Stocks Are Winners
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Why NVIDIA Is More of a Screaming Buy Than Ever
- The 3 Best Fintech Stocks to Buy Now
- Don’t Miss These 3 Stocks Set to Defy Expectations in September
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.